Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CANVAXIN
- Development stage
- Discontinued
- Lead developer
- CancerVax
- Modality
- Vaccines & Immunotherapeutics, Cell Therapies
- Administration
- Intradermal
01
Overview
CANVAXIN is an allogeneic, whole-cell, polyvalent therapeutic cancer vaccine developed as an immunotherapy for melanoma. It consists of three viable, irradiated, replication-incompetent melanoma cell lines and is designed to stimulate the patient's immune system to recognize and attack melanoma cells. The vaccine was primarily investigated as a postoperative adjuvant treatment for patients with stage III and IV melanoma but also showed promise in stage II disease. Clinical trials indicated a correlation between immune response and clinical outcomes; however, phase III studies were discontinued due to lack of survival benefit. Development and manufacturing have been terminated[1][2][3][4][5][7].
- Brand names
- CANVAXIN
- Other names
- Onamelatucel-LCancerVax vaccine
Beyond the preview
Go deeper on CANVAXIN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CANVAXIN.